Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a beta value of 1.07 and has seen 403.28 million shares traded in the last trading session. The company, currently valued at $206.23M, closed the last trade at $0.57 per share which meant it gained $0.22 on the day or 64.13% during that session. The LXRX stock price is -333.33% off its 52-week high price of $2.47 and 50.88% above the 52-week low of $0.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 44.17 million shares traded. The 3-month trading volume is 6.32 million shares.
The consensus among analysts is that Lexicon Pharmaceuticals Inc (LXRX) is Buy stock at the moment, with a recommendation rating of 2.17. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.1.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Sporting 64.13% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the LXRX stock price touched $0.57 or saw a rise of 18.57%. Year-to-date, Lexicon Pharmaceuticals Inc shares have moved -22.75%, while the 5-day performance has seen it change 57.08%. Over the past 30 days, the shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) have changed -14.85%. Short interest in the company has seen 39.26 million shares shorted with days to cover at 4.04.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 90.5% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -952.63% off the targeted high while a plunge would see the stock gain -952.63% from current levels.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
The company’s shares have lost -63.66% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -72.33%.
4 analysts offering their estimates for the company have set an average revenue estimate of 1.26M for the current quarter. 4 have an estimated revenue figure of 1.33M for the next ending quarter. Year-ago sales stood 1.13M and 1.65M respectively for this quarter and the next, and analysts expect sales will grow by 11.73% for the current quarter and -72.33% for the next.
Earnings growth for 2025 is a modest 41.27% while over the next 5 years, the company’s earnings are expected to increase by 22.79%.
LXRX Dividends
Lexicon Pharmaceuticals Inc is expected to release its next earnings report on 2025-Mar-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Insiders own 1.19% of the company shares, while shares held by institutions stand at 84.11% with a share float percentage of 85.13%. Investors are also buoyed by the number of investors in a company, with Lexicon Pharmaceuticals Inc having a total of 168.0 institutions that hold shares in the company. The top two institutional holders are ARTAL GROUP S.A. with over 175.1 million shares worth more than $294.17 million. As of 2024-06-30, ARTAL GROUP S.A. held 56.3318% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 38.69 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.99 million and represent 12.4462% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund . As of Jan 31, 2025 , the former fund manager holds about 4.66% shares in the company for having 16.86 shares of worth $9.62 million while later fund manager owns 5.54 shares of worth $3.16 million as of Jan 31, 2025 , which makes it owner of about 1.53% of company’s outstanding stock.
